ERC Starting Grant · 2023
Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment
Cancer immunotherapies with chimeric antigen receptor (CAR) T cells have shown dramatic clinical efficacy in patients with B cell neoplasms. Thus, their clinical use is expected to increase considerably in the near future. However, for poorly understood reasons, not all patients with lymphoma benefit from these expensive therapies. The ability to stratify patients into probable responders vs. non-responders prior to immunotherapy will improve treatment efficacy, limit patient exposure to adverse effects, and mitigate the significant economic costs associated with these therapies. We and others have previously demonstrated that effective antitumoral immunity requires complex, spatially…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.